Finanzen von Valion Bio Inc (VBIO)VBIOValion Bio Inc

Evaluating the bottom line, Valion Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -476.11%, provide a clear picture of how effectively VBIO converts its operational activities into shareholder value.

In the context of the broader market, VBIO competes directly with industry leaders such as NXL and BRTX. With a market capitalization of $1.19M, it holds a significant position in the sector. When comparing efficiency, VBIO's gross margin of N/A stands against NXL's 73.16% and BRTX's 68.13%. Such benchmarking helps identify whether Valion Bio Inc is trading at a premium or discount relative to its financial performance.

Tivic Health has reported zero revenue in several quarters, with a net income loss of $6.4 million in Q2 2026 and a gross margin of -99.32% in Q3 2025, indicating severe financial distress. The company's total debt has increased to $7.4 million, while total equity has fallen to $11.9 million, reflecting a deteriorating financial position.